Adma Biologics (NASDAQ: ADMA) reported Q2 EPS of ($0.44), $0.08 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $1.3 million, versus $1.5 million reported last year.

For earnings history and earnings-related data on Adma Biologics (ADMA) click here.